Based on clues provided by a study with transgenic mice, a research group at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), has developed a strategy that will be tested as the first treatment for people with hereditary inclusion body myopathy (HIBM), a rare, degenerative muscle disease.
Oregon Health & Science University Cancer Institute researchers have identified a protein that is a strong indicator of survival for men with advanced prostate cancer.
Researchers at Eli Lilly and Company are actively investigating the efficacy and safety of lung cancer treatments ALIMTA (pemetrexed for injection) and GEMZAR (gemcitabine HCl for injection) in treating non-small cell lung cancer in African-Americans, Hispanics and other diverse populations.
University Hospitals Case Medical Center (UHCMC) and Case Western Reserve University School of Medicine are part of a nationwide research study to determine the safety and effectiveness of a new smallpox vaccine geared toward adults ages 18 to 34 who have never been vaccinated against the disease.
Early results from a three-site federal study show mice live longer when fed an anti-inflammatory substance found in the creosote bush. The substance extended median lifespan. Whether it allows the mice to live beyond their maximum expected lifespan will be known in six to 10 months.
Directly observed antiretroviral therapy is a promising strategy to ensure that HIV-infected children in developing countries take life-saving medications, new research from The Warren Alpert Medical School of Brown University shows.
Researchers in endocrinology and obstetrics and gynecology at Cedars-Sinai Medical Center will make several presentations at the upcoming annual meetings of two medical organizations ? the Androgen Excess Society (June 1, 2007) and the Endocrine Society (June 2-5, 2007).
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI; Accentia) reports that the Mayo Medical and Graduate Schools and the Virginia Bioinformatics Institute have been awarded a National Institute of Health (NIH) grant of $2.4 million for a project entitled “The Pathogenesis of Chronic Rhinosinusitis.”
Researchers at Queen Mary University London and the University of Leicester and have today (Friday June 1) announced a potential breakthrough in the treatment of a rare but devastating medical condition that can affect children and young people.
The U.S. Food and Drug Administration (FDA) today issued final recommendations to increase the supply of safe and effective influenza vaccines for both seasonal and pandemic use.